In a letter to shareholders today, San Diego’s Amylin Pharmaceuticals (NASDAQ: ALMN) urges them to vote for the company’s slate of directors on a blue proxy card. Amylin’s annual meeting will be held on May 27th. The diabetes drug developer asks shareholders to discard gold or white proxy cards with board candidates nominated by billionaire Carl Icahn or Eastbourne Capital Management. Amylin defends its policy in its letter, citing the opportunity of its exenatide diabetes drug, and criticizing Icahn and Eastbourne for “fundamentally misunderstanding” the company.
By posting a comment, you agree to our terms and conditions.